Krystal Biotech (KRYS) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 74.9% versus a loss of 6.8%. Over five years, KRYS leads with a +571.8% price change compared with -16.4% for QGEN. Krystal Biotech is the larger company by market cap ($9.83 billion vs $9.37 billion), about 1.0 times the size.
On valuation, Qiagen N.V. trades at a lower forward P/E (17.4x vs 35.8x for Krystal Biotech). Qiagen N.V. pays a dividend yielding 0.80%, while Krystal Biotech does not currently pay one. Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 20.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | QGEN |
|---|---|---|
| Share price | $332.01 | $45.40 |
| Market cap | $9.83B | $9.37B |
| 1-day change | +1.44% | +1.95% |
| YTD return | +32.76% | -0.98% |
| 1-year return | +74.86% | -6.76% |
| 5-year return | +571.80% | -16.44% |
| P/E ratio (TTM) | 41.60 | 23.05 |
| Forward P/E | 35.83 | 17.38 |
| EPS (TTM) | $7.98 | $1.97 |
| Dividend yield | 0.00% | 0.80% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | $389.13M | $2.09B |
| Revenue growth (YoY) | +33.94% | +5.65% |
| Net income (latest FY) | $204.83M | $424.88M |
| Gross margin | — | 62.18% |
| Operating margin | 41.45% | 22.29% |
| Net margin | 52.64% | 20.33% |
| 52-week high | $382.54 | $57.82 |
| 52-week low | $179.19 | $32.53 |
| Distance from 52-week high | -13.21% | -21.48% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +18.10% | +4.12% |
| Average volume | 381.18K | 2.58M |
| Shares outstanding | 29.60M | 206.50M |
| Employees | 295 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed QGEN by 81.6 percentage points over the past year.
- Krystal Biotech trades at a higher earnings multiple (41.6x vs 23.0x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 20.3 cents for Qiagen N.V..
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +5.65%).
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
KRYS vs QGEN FAQ
Which is bigger, Krystal Biotech or Qiagen N.V.?
Krystal Biotech (KRYS) is larger, with a market capitalization of $9.83B compared with $9.37B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, KRYS or QGEN?
KRYS returned +74.86% over the past 12 months, compared with -6.76% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KRYS or QGEN?
QGEN has the lower trailing P/E at 23.0, versus 41.6 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Krystal Biotech or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.80%, while Krystal Biotech does not currently pay a regular dividend.
Are Krystal Biotech and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.